We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall
Covid vaccine maker looks to use machine learning to help discover new treatments
Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS
Success in battle against Covid does not ensure success against tumours, but should narrow the odds
Fall from €3.2bn in the third quarter of 2021 to €1.8bn
Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic
Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections
US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic
Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials
German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations
The latest strains have spread fast and governments are trying to catch up
Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements
New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain
‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants
US prepares to roll out jabs to last age group without access once regulatory approval is received
The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven
German biotech’s promising early-stage results make it a sought-after partner
German biotech maintains guidance but prepares for fall in sales because of jab oversupply
Remuneration at the three big jab makers reflects surge in value of share options
German biotech plans to boost R&D spending by 50% as quarterly earnings beat forecasts
Johnson government announces plan after similar moves in Scotland and Wales
First human study of variant-specific jab by big western drugmaker could prompt shift in manufacturing
Hopes early warning system will give policymakers and vaccine producers more time to address health risks
International Edition
